Guardant Health Inc. (GH) Reports Q3 Loss of $1.94, Revenues Beat; Offers FY18 Revenue Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. XYZ
9. FISV
10. CVS

Go back to Guardant Health Inc. (GH) Reports Q3 Loss of $1.94, Revenues Beat; Offers FY18 Revenue Guidance Above Consensus

Guardant Health Reports Third Quarter 2018 Financial Results

November 19, 2018 4:05 PM EST

Revenue growth of 95% over prior year period

REDWOOD CITY, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, today reported financial results for the third quarter ended September 30, 2018.

Recent Highlights

Revenues of $21.7 million for the third quarter of 2018, representing a 95% increase over the third quarter of 2017Reported 7,027 tests to clinical customers and 2,505 tests to biopharmaceutical customers in... More